A Phase II Trial of Trisenox Plus Thalomid as Treatment in Patients With Myelodysplastic Syndrome
Status:
Terminated
Trial end date:
2007-05-01
Target enrollment:
Participant gender:
Summary
This is a Phase II, open-label, non-randomized study in patients with low, intermediate-1,
intermediate-2, or high-risk MDS (defined by IPSS).
Each cycle of treatment will be 6 weeks in length. Patients will be evaluated every 6 weeks
for response. Patients will be treated for a minimum of 12 weeks even in the absence of
response. Following 12 weeks of treatment, patients will continue to receive study treatment
until disease progression or unacceptable toxicity.